Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
17
WINT Quote, Financials, Valuation and Earnings
Last price:
$0.33
Seasonality move
:
-9.01%
Day range:
$0.32 - $0.34
52-week range:
$0.32 - $14.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.26x
P/B ratio:
0.69x
Volume:
457.9K
Avg. volume:
933.7K
1-year change:
-97.47%
Market cap:
$3M
Revenue:
--
EPS (TTM):
-$16.53
Analysts' Opinion
-
Consensus RatingWindtree Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Windtree Therapeutics has an estimated upside of 1976.54% from its current price of $0.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.34.
Fair Value
-
According to the consensus of 0 analysts, Windtree Therapeutics has 1976.54% upside to fair value with a price target of -- per share.
WINT vs. S&P 500
-
Over the past 5 trading days, Windtree Therapeutics has underperformed the S&P 500 by -2.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Windtree Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Windtree Therapeutics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Windtree Therapeutics reported revenues of --.
Earnings Growth
-
Windtree Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Windtree Therapeutics reported earnings per share of -$4.23.
Enterprise value:
1.5M
EV / Invested capital:
--
Price / LTM sales:
0.26x
EV / EBIT:
--
EV / Revenue:
2.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$25.9M | -$16M | -$25.6M | -$4.7M | -$4.7M | |
| EBITDA | -$43.6M | -$25.8M | -$9.1M | -$4.3M | -$2.8M | |
| Diluted EPS | -$1,290.42 | -$364.77 | -$16.53 | -$15.47 | -$4.23 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24M | $26.4M | $10M | $8.9M | $3.9M | |
| Total Assets | $118.5M | $84.8M | $48.1M | $36.1M | $30.4M | |
| Current Liabilities | $6.3M | $5.1M | $4M | $3.7M | $14.4M | |
| Total Liabilities | $42.8M | $34.6M | $30.7M | $28.6M | $26M | |
| Total Equity | $75.7M | $50.2M | $17.4M | $7.5M | $4.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21M | -$13.3M | -$15.3M | -$3.9M | -$6.4M | |
| Cash From Investing | $24K | -- | -- | -$15K | -- | |
| Cash From Financing | $4.9M | $12.2M | $10.1M | -$233K | $6.9M | |
| Free Cash Flow | -$21.2M | -$13.3M | -$15.3M | -$3.9M | -$6.4M | |
WINT
Sector
Market Cap
$3M
$44.6M
Price % of 52-Week High
2.29%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-97.47%
-29.09%
Beta (5-Year)
0.540
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.36
200-day SMA
Sell
Level
$4.12
Bollinger Bands (100)
Sell
Level
-0.61 - 7.41
Chaikin Money Flow
Sell
Level
-659.6M
20-day SMA
Sell
Level
$0.43
Relative Strength Index (RSI14)
Sell
Level
30.42
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-91.7051
50-day SMA
Sell
Level
$0.59
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
544.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Stock Forecast FAQ
In the current month, WINT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The WINT average analyst price target in the past 3 months is --.
-
Where Will Windtree Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Windtree Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Windtree Therapeutics?
Analysts are divided on their view about Windtree Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Windtree Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Windtree Therapeutics's Price Target?
The price target for Windtree Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is WINT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Windtree Therapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of WINT?
You can purchase shares of Windtree Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Windtree Therapeutics shares.
-
What Is The Windtree Therapeutics Share Price Today?
Windtree Therapeutics was last trading at $0.33 per share. This represents the most recent stock quote for Windtree Therapeutics. Yesterday, Windtree Therapeutics closed at $0.34 per share.
-
How To Buy Windtree Therapeutics Stock Online?
In order to purchase Windtree Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
